SCHEMBL2404540

SCHEMBL2404540

O=C(NC1(c2ccccc2)CC1)c1c(CN2CCC(N3CCCCC3)CC2)c(-c2cccc(C(F)(F)F)c2)nc2cc(Br)ccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TRPV4 Q9HBA0 19/20 1.00
TACR2 P21452 2/20 0.64
TACR3 P29371 2/20 0.64
KCNH2 Q12809 1/20 0.64
CACNA1C Q13936 1/20 0.64
SCN5A Q14524 1/20 0.64
NR1I2 O75469 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2400335 0.96 TRPV4 (0.92) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL2371586 0.93 TRPV4 (0.88) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL6845630 0.93 TRPV4 (1.00) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL2387514 0.92 TRPV4 (0.99) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL25209401 0.91 TRPV4 (0.90) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL6845465 0.91 TRPV4 (0.85) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL6870097 0.91 TRPV4 (0.83) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL6845631 0.90 TRPV4 (1.00) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL2401714 0.90 TRPV4 (0.88) TRPV4TACR2TACR3KCNH2CACNA1C
SCHEMBL6845669 0.90 TRPV4 (0.83) TRPV4TACR2TACR3KCNH2CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250352615-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 UNIV DUKE (US) 2025-11-20 US claimed
WO-2025096549-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF BRAIN INJURIES OHIO STATE INNOVATION FOUNDATION (US) 2025-05-08 WO claimed
WO-2025051930-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRPV4 INHIBITOR FOR USE IN THE PREVENTION OR TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS (CCM) UNIVERSITE GRENOBLE ALPES (FR) 2025-03-13 WO claimed
EP-4520331-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRPV4 INHIBITOR FOR USE IN THE PREVENTION OR TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS (CCM) Université Grenoble Alpes (FR) 2025-03-12 EP claimed
WO-2025029629-A2 TRPV4 INHIBITION TO TREAT ARRHYTHMIC CARDIOMYOPATHY DUKE UNIVERSITY (US) 2025-02-06 WO claimed
WO-2024217445-A1 USE OF TRPV4 INHIBITOR IN TREATMENT OF CHRONIC HEPATITIS B, HEPATIC FIBROSIS, AND LIVER CANCER 河北乌图药业有限公司 2024-10-24 WO claimed
WO-2024216180-A1 TARGETING THE PANX1–P2Y2R–TRPV4 PATHWAY TO TREAT LUNG ISCHEMIA-REPERFUSION INJURY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-10-17 WO claimed
EP-3585371-B1 METHODS OF INHIBITING SERUM GLUCOCORTICOID INDUCED KINASE 1 (SGK1) AS A TREATMENT FOR SALT AND WATER BALANCE DISEASES UNIV INDIANA RES & TECH CORP (US) 2024-07-10 EP claimed
CN-117205319-A Application of TRPA1 ion channel as drug target in paraquat poisoning 中国人民解放军军事科学院军事医学研究院 2023-12-12 CN claimed
CN-116814528-A Culture medium, polycystic kidney organoid culture method and application 山东大学 2023-09-29 CN claimed
CN-116726013-A Application of GSK2193874 in preventing and treating painful diabetic peripheral neuropathy 中国科学院大学深圳医院(光明) 2023-09-12 CN claimed
US-20230255965-A1 TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES RAQUALIA PHARMA INC. (JP) 2023-08-17 US claimed
CN-116510017-A Application of TRPV4 inhibitor in treatment of chronic hepatitis B, liver fibrosis and liver cancer 河北乌图药业有限公司 2023-08-01 CN claimed
US-11701358-B2 Methods of inhibiting serum glucocorticoid induced kinase 1 (SGKI) as a treatment for salt and water balance diseases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-07-18 US claimed
WO-2023091901-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 DUKE UNIVERSITY (US) 2023-05-25 WO claimed
EP-4183415-A1 TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE RaQualia Pharma Inc. (JP) 2023-05-24 EP claimed
CN-115776890-A TRPV4 inhibitors as therapeutic agents for eye diseases 拉夸里亚创药株式会社 2023-03-10 CN claimed
US-11318140-B2 Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2022-05-03 US claimed
US-11058707-B2 Methods for treating ischemic heart disease by targeting TRPV4 NORTHEAST OHIO MEDICAL UNIVERSITY (US) 2021-07-13 US claimed
US-12582649-B2 Compositions and methods for hair follicle regeneration WASHINGTON UNIVERSITY (US) 2026-03-24 US disclosed
US-20260048098-A1 TREATMENT OF RETINAL GANGLION CELL LOSS PS THERAPY INC (US) 2026-02-19 US disclosed
US-12552773-B2 Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof JIANGNAN UNIVERSITY (CN) 2026-02-17 US disclosed
US-20250352615-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 UNIV DUKE (US) 2025-11-20 US disclosed
CN-120536343-A Method for constructing polycystic kidney disease model and application of polycystic kidney disease model in drug screening 山东大学 2025-08-26 CN disclosed
CN-116814528-B Culture medium, polycystic kidney organoid culture method and application 山东大学 2025-06-17 CN disclosed
CN-116814528-B Culture medium, polycystic kidney organoid culture method and application 山东大学 2025-06-17 CN disclosed
WO-2025096549-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OF BRAIN INJURIES OHIO STATE INNOVATION FOUNDATION (US) 2025-05-08 WO disclosed
CN-119757270-A Medicinal material quality grade evaluation method for near infrared rapid detection of content of calcium antagonism efficacy component in magnolia officinalis 广西中医药大学 2025-04-04 CN disclosed
WO-2025051930-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRPV4 INHIBITOR FOR USE IN THE PREVENTION OR TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS (CCM) UNIVERSITE GRENOBLE ALPES (FR) 2025-03-13 WO disclosed
EP-4520331-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRPV4 INHIBITOR FOR USE IN THE PREVENTION OR TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS (CCM) Université Grenoble Alpes (FR) 2025-03-12 EP disclosed
WO-2025029629-A2 TRPV4 INHIBITION TO TREAT ARRHYTHMIC CARDIOMYOPATHY DUKE UNIVERSITY (US) 2025-02-06 WO disclosed
US-20240385177-A1 Screening Method Using Brown Adipocytes KATAOKA CORPORATION (JP) 2024-11-21 US disclosed
WO-2024217445-A1 USE OF TRPV4 INHIBITOR IN TREATMENT OF CHRONIC HEPATITIS B, HEPATIC FIBROSIS, AND LIVER CANCER 河北乌图药业有限公司 2024-10-24 WO disclosed
WO-2024216180-A1 TARGETING THE PANX1–P2Y2R–TRPV4 PATHWAY TO TREAT LUNG ISCHEMIA-REPERFUSION INJURY UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2024-10-17 WO disclosed
CN-118389488-B Temperature-sensitive TRPS ion channel-mediated activation type microwave nerve regulation technology and application thereof 中国人民解放军军事科学院军事医学研究院 2024-10-11 CN disclosed
US-20240326041-A1 MICROFLUIDIC INDUCTION OF RESEARCH BASED NEURAL INJURY WORCESTER POLYTECH INST (US) 2024-10-03 US disclosed
WO-2024206784-A1 MICROFLUIDIC INDUCTION OF RESEARCH BASED NEURAL INJURY WORCESTER POLYTECHNIC INSTITUTE (US) 2024-10-03 WO disclosed
CN-117205319-B Application of HC030031 in preparation of medicine for preventing or treating lung injury caused by paraquat poisoning 中国人民解放军军事科学院军事医学研究院 2024-09-03 CN disclosed
EP-4407040-A1 SCREENING METHOD USING BROWN ADIPOCYTES Kataoka Corporation (JP) 2024-07-31 EP disclosed
US-12048750-B2 Tissue-homing peptide conjugates and methods of use thereof Blaze Bioscience, Inc. (US) 2024-07-30 US disclosed
CN-118389488-A Temperature-sensitive TRPS ion channel-mediated activation type microwave nerve regulation technology and application thereof 中国人民解放军军事科学院军事医学研究院 2024-07-26 CN disclosed
EP-3585371-B1 METHODS OF INHIBITING SERUM GLUCOCORTICOID INDUCED KINASE 1 (SGK1) AS A TREATMENT FOR SALT AND WATER BALANCE DISEASES UNIV INDIANA RES & TECH CORP (US) 2024-07-10 EP disclosed
US-12013398-B2 Compositions and methods for treatment of invasive cancers THE GEORGE WASHINGTON UNIVERSITY (US) 2024-06-18 US disclosed
CN-117388500-B Application of TRPV4 as drug target in coronavirus infection anti-inflammatory drug 暨南大学 2024-06-04 CN disclosed
US-11883344-B2 Neural stimulation in vitro and in vivo by photoacoustic nanotransducers TRUSTEES OF BOSTON UNIVERSITY (US) 2024-01-30 US disclosed
CN-117388500-A Application of TRPV4 as drug target in coronavirus infection anti-inflammatory drug 暨南大学 2024-01-12 CN disclosed
US-20240002437-A1 COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES NATIONAL INSTITUTES OF HEALTH 2024-01-04 US disclosed
CN-117205319-A Application of TRPA1 ion channel as drug target in paraquat poisoning 中国人民解放军军事科学院军事医学研究院 2023-12-12 CN disclosed
US-11773445-B1 Diagnostic methods GRIFFITH UNIVERSITY 2023-10-03 US disclosed
CN-116814528-A Culture medium, polycystic kidney organoid culture method and application 山东大学 2023-09-29 CN disclosed
CN-116814528-A Culture medium, polycystic kidney organoid culture method and application 山东大学 2023-09-29 CN disclosed
CN-116726013-A Application of GSK2193874 in preventing and treating painful diabetic peripheral neuropathy 中国科学院大学深圳医院(光明) 2023-09-12 CN disclosed
CN-116726013-A Application of GSK2193874 in preventing and treating painful diabetic peripheral neuropathy 中国科学院大学深圳医院(光明) 2023-09-12 CN disclosed
CN-116726013-A Application of GSK2193874 in preventing and treating painful diabetic peripheral neuropathy 中国科学院大学深圳医院(光明) 2023-09-12 CN disclosed
US-20230277528-A1 COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION WASHINGTON UNIVERSITY (US) 2023-09-07 US disclosed
US-20230255965-A1 TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES RAQUALIA PHARMA INC. (JP) 2023-08-17 US disclosed
WO-2023150077-A1 NEURAL STIMULATION IN VITRO AND IN VIVO BY PHOTOACOUSTIC NANOTRANSDUCERS TRUSTEES OF BOSTON UNIVERSITY (US) 2023-08-10 WO disclosed
US-20230240935-A1 NEURAL STIMULATION IN VITRO AND IN VIVO BY PHOTOACOUSTIC NANOTRANSDUCERS TRUSTEES OF BOSTON UNIVERSITY (US) 2023-08-03 US disclosed
CN-116510017-A Application of TRPV4 inhibitor in treatment of chronic hepatitis B, liver fibrosis and liver cancer 河北乌图药业有限公司 2023-08-01 CN disclosed
US-11701358-B2 Methods of inhibiting serum glucocorticoid induced kinase 1 (SGKI) as a treatment for salt and water balance diseases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2023-07-18 US disclosed
US-20230211000-A1 TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF Blaze Bioscience, Inc. 2023-07-06 US disclosed
WO-2023091901-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 DUKE UNIVERSITY (US) 2023-05-25 WO disclosed
WO-2023091901-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 DUKE UNIVERSITY (US) 2023-05-25 WO disclosed
EP-4183415-A1 TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE RaQualia Pharma Inc. (JP) 2023-05-24 EP disclosed
WO-2023048060-A1 SCREENING METHOD USING BROWN ADIPOCYTES 株式会社片岡製作所 2023-03-30 WO disclosed
CN-115776890-A TRPV4 inhibitors as therapeutic agents for eye diseases 拉夸里亚创药株式会社 2023-03-10 CN disclosed
US-11559580-B1 Tissue-homing peptide conjugates and methods of use thereof Blaze Bioscience, Inc. (US) 2023-01-24 US disclosed
US-20220341937-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INVASIVE CANCERS THE GEORGE WASHINGTON UNIVERSITY 2022-10-27 US disclosed
WO-2022226038-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INVASIVE CANCERS THE GEORGE WASHINGTON UNIVERSITY (US) 2022-10-27 WO disclosed
US-20220305088-A1 METHODS AND COMPOSITIONS FOR TREATING A MICROBIAL INFECTION PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-09-29 US disclosed
US-20220273608-A1 Methods for Treating Bone-Related Disorders UNIVERSITY OF MARYLAND, BALTIMORE (US) 2022-09-01 US disclosed
US-11400136-B2 Methods and compositions for treating a microbial infection PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-08-02 US disclosed
US-11331393-B2 Renal-homing peptide conjugates and methods of use thereof Blaze Bioscience, Inc. (US) 2022-05-17 US disclosed
US-20220144804-A1 Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof JIANGNAN UNIVERSITY (CN) 2022-05-12 US disclosed
WO-2022095461-A1 COMPOUND FOR SPECIFICALLY ENHANCING SPATIAL COUPLING DEGREE OF TRPV4-KCA2.3 COMPLEX AND USE THEREOF 江南大学 2022-05-12 WO disclosed
WO-2022093684-A1 COMPOSITIONS AND METHODS OF TREATING INFLAMMATORY LUNG DISEASES ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2022-05-05 WO disclosed
US-11318140-B2 Use of TRPV4 antagonists to ameliorate hydrocephalus and related materials and methods INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2022-05-03 US disclosed
US-11241442-B2 Methods of use for TRP channel antagonist-based combination cancer therapies PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-02-08 US disclosed
CN-113975376-A Application method of nanoparticle-based targeted Piezo1 protein in acute lung injury 苏州大学附属第一医院 2022-01-28 CN disclosed
US-20210311075-A1 METHODS FOR DETECTING DISORDERS RELATED TO CALCIUM DISCHARGE FROM INTRACELLULAR STORES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-10-07 US disclosed
US-11058707-B2 Methods for treating ischemic heart disease by targeting TRPV4 NORTHEAST OHIO MEDICAL UNIVERSITY (US) 2021-07-13 US disclosed
US-20210128581-A1 METHODS OF USE FOR TRP CHANNEL ANTAGONIST-BASED COMBINATION CANCER THERAPIES PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2021-05-06 US disclosed
US-20180280562-A1 Fibrous Structures Comprising Sensates THE PROCTER & GAMBLE COMPANY 2018-10-04 US disclosed
WO-2011119704-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2011-09-29 WO disclosed
WO-2011119704-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2011-09-29 WO disclosed
WO-2011119704-A1 TRPV4 ANTAGONISTS GLAXOSMITHKLINE LLC (US) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12048750-B2 Tissue-homing peptide conjugates and methods of use thereof CXCL12, CCL2, CD44 TRPV4 3445/4885TACR2 346/4885TACR3 420/4885
US-20220144804-A1 Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof TRPV4, TRPV2, TRPV3 TRPV4 1/4885TACR2 437/4885TACR3 999/4885
US-12552773-B2 Compound for specifically enhancing spatial coupling degree of TRPV4-KCa2.3 complex and use thereof TRPV4, TRPV2, TRPV6 TRPV4 1/4885TACR2 446/4885TACR3 1443/4885
US-20230277528-A1 COMPOSITIONS AND METHODS FOR HAIR FOLLICLE REGENERATION TRPV4, TRPC4, S100A4 TRPV4 1/4885TACR2 248/4885TACR3 326/4885
US-20260048098-A1 TREATMENT OF RETINAL GANGLION CELL LOSS TRPV4, TRPV3, TRPV5 TRPV4 1/4885TACR2 189/4885TACR3 305/4885
US-11331393-B2 Renal-homing peptide conjugates and methods of use thereof CXCL12, ATP6V1B1, VIP TRPV4 4181/4885TACR2 219/4885TACR3 270/4885
US-20230211000-A1 TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF CXCL12, CCL2, CD44 TRPV4 3445/4885TACR2 346/4885TACR3 420/4885
US-11701358-B2 Methods of inhibiting serum glucocorticoid induced kinase 1 (SGKI) as a treatment for salt and water balance diseases SGK1, SGK3, SGK2 TRPV4 1665/4885TACR2 356/4885TACR3 1480/4885
US-11559580-B1 Tissue-homing peptide conjugates and methods of use thereof CXCL12, CCL2, CD44 TRPV4 3445/4885TACR2 346/4885TACR3 420/4885
US-20250352615-A1 COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4 PIEZO1, PLA2G4A, TRPV4 TRPV4 3/4885TACR2 1320/4885TACR3 1771/4885
US-20230255965-A1 TRPV4 INHIBITOR AS A THERAPEUTIC AGENT FOR OCULAR DISEASES TRPV4, TRPV5, TRPV2 TRPV4 1/4885TACR2 314/4885TACR3 885/4885
US-12582649-B2 Compositions and methods for hair follicle regeneration TRPV4, TRPV6, TRPM4 TRPV4 1/4885TACR2 870/4885TACR3 1521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.